Dr Reddy's has moved one notch closer to buying out US based generic drug maker Bradley pharma but, a few other big players pose a challenge to the deal.
The battle for US based generic drug maker Bradley pharma is intensifying. The Indian challenge is from Dr Reddy's Labs, which is learnt to have moved into, round two of the bidding process. Bradley’s product portfolio includes a few high profit margin dermatology products and that’s expected to benefit Dr Reddy's. But, that portfolio has attracted attention from Archimedes Pharma and Nycomed. Archimedes is a company promoted by private equity giant Warburg Pincus while Nycomed has the backing from Blackstone.
Read more in The Moneycontrol article.
No comments:
Post a Comment